Rule 1: Compounds containing functional groups such as "-COOH", "-OH", long carbon chain structures, or "-NO2" may potentially cause respiratory, thoracic, and mediastinal disorders.
Rule 2: The presence of nitro groups in a compound increases its likelihood of causing adverse effects on respiratory, thoracic and mediastinal disorders due to its toxic and carcinogenic properties. 
Rule 3: Molecular structure, particularly including elements like chlorine, significantly determines the potential adverse effects of a molecule on these organs.
Rule 4: The charge state of a molecule, such as presence of magnesium ions (Mg+2), could affect its potential to cause adverse effects. 
Rule 5: Functional groups like cyanide or fluoride, a conjugated system of multiple double bonds, or the presence of aromatic rings in a molecular structure have potential toxicity towards living organisms, thus possibly causing respiratory and related disorders.
Rule 6: Presence of "-Cl" or "-Br" in the molecular structure, or a nitro group or sulfonamide group may lead to respiratory, thoracic and mediastinal disorders due to their reactive nature.
Rule 7: The presence of functional groups leading to respiratory disorders could also depend on other factors like lipophilicity, weight, size and ability to cross cell membranes.
Rule 8: Elements with high electronegativity, like fluorine or chlorine, in a compound might increase probability of causing respiratory, thoracic and mediastinal disorders.
Rule 9: Compounds with halogen atoms, phosphate, or sulfonyl groups among others are potential causes for respiratory disorders due to their reactivity and metabolic stability.
Rule 10: Compounds containing aromatic rings and conjugated double bonds can potentially increase the likelihood of respiratory, thoracic and mediastinal disorders.
Rule 1: Molecules containing a sulfur atom bonded to two carbon atoms in a ring structure may have potential to cause respiratory, thoracic and mediastinal disorders.
Rule 2: Chlorine atoms attached to a benzene ring in a molecule may lead to respiratory, thoracic and mediastinal disorders.
Rule 3: The presence of a nitro group (-NO2) or a carbonyl group (-C=O) connected to a phenyl ring in a molecule may cause respiratory, thoracic and mediastinal disorders.
Rule 4: Molecules with functional groups like "-COOH" or "-OH", are likely to adverse effects in the respiratory system.
Rule 5: Benzene rings present in molecular structures may potentially cause adverse effects on the immune system.
Rule 6: Molecules containing a nitro group (-NO2) could potentially lead to adverse effects on the cardiovascular system.
Rule 7: The presence of functional groups "-COOH" or "-SO3H" in molecular structures indicates a probability of causing respiratory, thoracic and mediastinal disorders.
Rule 8: Long carbon chains in a molecular structure may increase the risk of respiratory, thoracic and mediastinal disorders.
Rule 9: Sulfonamide group (-SO2NH-) or a nitro group (-NO2) in a molecule can cause adverse effects related to respiratory, thoracic, and mediastinal disorders.
Rule 10: The presence of negatively charged ions such as [Ca+2] in molecular structures may possibly cause respiratory, thoracic and mediastinal disorders.
Rule 11: A chlorine atom bonded to a carbon atom in para position relative to a carbonyl group (C=O) in a molecule could cause adverse effects related to respiratory, thoracic and mediastinal disorders.
Rule 12: Molecules with a nitro group (-NO2) could lead to respiratory, thoracic, and mediastinal disorders.
Rule 13: Molecules containing a sulfonyl group (-SO2R) may lead to respiratory, thoracic, and mediastinal disorders.
Rule 14: Molecules that contain a chlorine atom attached to an aromatic ring may potentially cause respiratory, thoracic, and mediastinal disorders.
Rule 15: Functional groups like carbonyl group (C=O) or carboxyl group (COOH) in the molecular structure may potentially cause adverse effects on respiratory, thoracic and mediastinal disorders.
Rule 16: The presence of aromatic rings in molecular structures may potentially cause adverse effects on respiratory, thoracic and mediastinal disorders.
Rule 17: Molecules containing a benzene ring attached to a carbonyl group (-C=O) through a single bond may have potential to cause respiratory, thoracic and mediastinal disorders.
Rule 18: Molecules containing a chlorine atom (-Cl) bonded to a carbon atom might potentially cause respiratory, thoracic and mediastinal disorders.
Rule 19: Molecules with a functional group like carbonyl or carboxyl in their structure could lead to respiratory, thoracic and mediastinal disorders.
Rule 20: Molecules that contain halogen atoms such as chlorine or fluorine could potentially cause adverse effects on the respiratory system. 
Rule 21: Molecules containing aromatic rings or conjugated double bonds may increase the risk of deteriorating respiratory system. 
Rule 22: Molecules with a sulfonyl group (-SO2-) or a carbonyl group (-C=O) in its structure are likely to cause respiratory, thoracic and mediastinal disorders.
Rule 23: Molecules containing a halogen atom like chlorine (Cl), fluorine (F), may cause adverse effects related to respiratory, thoracic and mediastinal disorders.
Rule 24: Molecules containing a nitro group (-NO2) in their structure may provoke respiratory, thoracic and mediastinal disorders. 
Rule 25: The presence of any functional group such as "-COOH" or "-SO3H" in the molecular structure suggests a likelihood of causing adverse effects on the respiratory system.
Rule 26: The presence of an aromatic ring in the molecular structure may potentially cause thoracic and mediastinal disorders.
Rule 27: The presence of any halogen atom like chlorine or fluorine in the molecular structure may potentially cause adverse effects on the cardiovascular system.
Rule 28: If a molecule contains a metal ion such as Ga+3 or K+, it may lead to adverse effects related to respiratory, thoracic and mediastinal disorders.
Rule 29: Molecules containing a functional group such as CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C or CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C, are likely to cause adverse effects related to respiratory, thoracic, and mediastinal disorders.
Rule 30: Molecules not containing a sulfonic acid group (-SO3H) are less likely to cause adverse effects related to respiratory, thoracic, and mediastinal disorders.
